Stockscreener 앱 받기
116.49
3.81%
4.28
시간 외 거래:
116.49
전일 마감가:
$112.21
열려 있는:
$114.08
하루 거래량:
944.78K
Relative Volume:
1.12
시가총액:
$5.68B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-17.84
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+8.63%
1개월 성능:
+17.83%
6개월 성능:
+30.54%
1년 성능:
+55.74%
1일 변동 폭
$113.61
$120.00
1주일 범위
$107.22
$120.00
52주 변동 폭
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
116.49 | 5.68B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Axsome Therapeutics, Inc. SEC 10-Q Report - TradingView
Voya Investment Management LLC Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Nigeria
Narcolepsy Market: Epidemiology, Therapies, Companies, - openPR.com
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 - Benzinga
Earnings call transcript: Axsome Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Axsome Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Axsome Q1 2025 slides: 62% revenue growth as CNS portfolio expands - Investing.com India
The three-year returns have been enviable for Axsome Therapeutics (NASDAQ:AXSM) shareholders despite underlying losses increasing - Yahoo Finance
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Axsome Therapeutics beats Q1 expectations, shares rise By Investing.com - Investing.com India
Axsome Therapeutics, Inc. Q1 Loss Decreases, Beats Estimates - Nasdaq
Axsome Therapeutics Q1 Loss Narrows, Revenue Increases - marketscreener.com
Axsome: Q1 Earnings Snapshot - San Francisco Chronicle
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Update - MarketBeat
Adage Capital Partners GP L.L.C. Has $5.08 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Ally Bridge Group NY LLC Purchases New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Boxer Capital Management LLC Buys Shares of 470,000 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
PDT Partners LLC Has $355,000 Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
First Trust Advisors LP Buys 11,488 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $193.00 - MarketBeat
Axsome Therapeutics (AXSM) Expected to Announce Earnings on Monday - MarketBeat
Tower Research Capital LLC TRC Buys 3,931 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Tri Locum Partners LP Purchases 158,048 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Envestnet Asset Management Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Canada Pension Plan Investment Board Makes New $347,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (AXSM) Supports Mental Health Awareness with - GuruFocus
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month - The Spec
Where are the Opportunities in (AXSM) - news.stocktradersdaily.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
RBC Capital Boosts Price Target for Axsome Therapeutics (AXSM) | - GuruFocus
Seven Springs Wealth Group LLC Acquires Shares of 4,005 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) - Benzinga
Barclays PLC Buys 36,203 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics price target raised to $193 from $190 at RBC Capital - TipRanks
RBC Raises Price Target on Axsome Therapeutics to $193 From $190, Keeps Outperform Rating - marketscreener.com
Hood River Capital Management LLC Buys 19,701 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS Adjusts Axsome Therapeutics Price Target to $143 From $149, Maintains Buy Rating - marketscreener.com
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline - Yahoo Finance
Marshall Wace LLP Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Raymond James Financial Inc. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Russell Investments Group Ltd. Buys 18,422 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):